Press coverage about Sucampo Pharmaceuticals (NASDAQ:SCMP) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sucampo Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.4850350658792 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
SCMP has been the topic of a number of research reports. Zacks Investment Research raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Tuesday, October 17th. Mizuho upped their price objective on Sucampo Pharmaceuticals from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, December 8th. UBS Group decreased their price objective on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, October 12th. Nomura assumed coverage on Sucampo Pharmaceuticals in a report on Monday, December 18th. They issued a “buy” rating and a $43.00 price objective on the stock. Finally, BidaskClub upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 5th. Six equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $21.58.
Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at $18.40 on Friday. The firm has a market capitalization of $858.12, a price-to-earnings ratio of -5.49, a PEG ratio of 5.07 and a beta of 1.45. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37. Sucampo Pharmaceuticals has a 1 year low of $9.30 and a 1 year high of $18.75.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. During the same period in the prior year, the company posted $0.30 EPS. The company’s revenue was up 5.9% compared to the same quarter last year. sell-side analysts anticipate that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current year.
In related news, insider Peter A. Kiener sold 50,000 shares of the company’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the sale, the insider now directly owns 52,023 shares in the company, valued at approximately $858,379.50. The sale was disclosed in a filing with the SEC, which is available through this link. 4.13% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Sucampo Pharmaceuticals (NASDAQ:SCMP) Given Media Sentiment Score of 0.16” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/12/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-sucampo-pharmaceuticals-scmp-share-price.html.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.